Morgan Stanley downgraded Intellia Therapeutics (NTLA) to Equal Weight from Overweight with a price target of $11, down from $56. The firm now expects a “more measured launch” of the company’s lead drug for transthyretin, and sees a lack of catalysts this year given recent discontinuation of its NTLA-3001 alpha-1 antitrypsin deficiency program. Intellia’s therapies face competition from therapies that do not edit the genes, the analyst tells investors in a research note.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics announces first patient dosed in Phase 3 NTLA-2002
- Intellia ATTR, HAE studies progressing as planned, says JPMorgan
- Intellia Therapeutics price target lowered to $40 from $60 at Oppenheimer
- Intellia Therapeutics price target lowered to $50 from $70 at BMO Capital
- Intellia Therapeutics price target lowered to $48 from $60 at Evercore ISI